RAF/MEK/mTOR inhibitors were among the top-ranked hits with suggested positive treatment effects on HR + BC of the young—being in line with our finding of gene expression patterns reflecting increased oncogenic signalling in tumours of the young. This evidence concerns the gene MTOR and breast cancer.